Docetaxel in the management of advanced pancreatic cancer

Gilberto Lopes, Caio Max S Rocha Lima

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The poor outcome of pancreatic cancer with conventional treatment options emphasizes the need for continued research. The benefits of gemcitabine in improving quality of life and survival have been established in patients with advanced pancreatic cancer. Randomized clinical trials studying the addition of a second drug to gemcitabine, either a classic cytotoxic (5-fluorouracil, cisplatin, irinotecan, pemetrexed, oxaliplatin, or exatecan) or targeted agents (ie, the farnesyl transferase inhibitor R115777 or the metalloproteinase inhibitor marimastat) have not resulted in improvement in survival compared with gemcitabine alone. Although limited activity of docetaxel in patients with pancreatic adenocarcinoma has been reported in single-agent studies, attractive efficacy results have been documented with docetaxel in combination with other chemotherapeutic agents for the management of advanced pancreatic cancer. Phase I and II trials of docetaxel in combination with gemcitabine, irinotecan, 5-fluorouracil, or thalidomide, as well as trials of docetaxel and radiotherapy, suggest that docetaxel combinations in pancreatic cancer should be further studied in randomized trials.

Original languageEnglish
JournalSeminars in Oncology
Volume32
Issue numberSUPPL. 4
DOIs
StatePublished - Apr 1 2005

Fingerprint

docetaxel
gemcitabine
Pancreatic Neoplasms
irinotecan
oxaliplatin
Fluorouracil
Pemetrexed
tipifarnib
Thalidomide
Survival
Metalloproteases
Transferases
Cisplatin
Adenocarcinoma
Radiotherapy
Randomized Controlled Trials
Quality of Life

ASJC Scopus subject areas

  • Oncology

Cite this

Docetaxel in the management of advanced pancreatic cancer. / Lopes, Gilberto; Rocha Lima, Caio Max S.

In: Seminars in Oncology, Vol. 32, No. SUPPL. 4, 01.04.2005.

Research output: Contribution to journalArticle

Lopes, Gilberto ; Rocha Lima, Caio Max S. / Docetaxel in the management of advanced pancreatic cancer. In: Seminars in Oncology. 2005 ; Vol. 32, No. SUPPL. 4.
@article{581b382face448e68f2201d9c3357574,
title = "Docetaxel in the management of advanced pancreatic cancer",
abstract = "The poor outcome of pancreatic cancer with conventional treatment options emphasizes the need for continued research. The benefits of gemcitabine in improving quality of life and survival have been established in patients with advanced pancreatic cancer. Randomized clinical trials studying the addition of a second drug to gemcitabine, either a classic cytotoxic (5-fluorouracil, cisplatin, irinotecan, pemetrexed, oxaliplatin, or exatecan) or targeted agents (ie, the farnesyl transferase inhibitor R115777 or the metalloproteinase inhibitor marimastat) have not resulted in improvement in survival compared with gemcitabine alone. Although limited activity of docetaxel in patients with pancreatic adenocarcinoma has been reported in single-agent studies, attractive efficacy results have been documented with docetaxel in combination with other chemotherapeutic agents for the management of advanced pancreatic cancer. Phase I and II trials of docetaxel in combination with gemcitabine, irinotecan, 5-fluorouracil, or thalidomide, as well as trials of docetaxel and radiotherapy, suggest that docetaxel combinations in pancreatic cancer should be further studied in randomized trials.",
author = "Gilberto Lopes and {Rocha Lima}, {Caio Max S}",
year = "2005",
month = "4",
day = "1",
doi = "10.1053/j.seminoncol.2005.04.003",
language = "English",
volume = "32",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Docetaxel in the management of advanced pancreatic cancer

AU - Lopes, Gilberto

AU - Rocha Lima, Caio Max S

PY - 2005/4/1

Y1 - 2005/4/1

N2 - The poor outcome of pancreatic cancer with conventional treatment options emphasizes the need for continued research. The benefits of gemcitabine in improving quality of life and survival have been established in patients with advanced pancreatic cancer. Randomized clinical trials studying the addition of a second drug to gemcitabine, either a classic cytotoxic (5-fluorouracil, cisplatin, irinotecan, pemetrexed, oxaliplatin, or exatecan) or targeted agents (ie, the farnesyl transferase inhibitor R115777 or the metalloproteinase inhibitor marimastat) have not resulted in improvement in survival compared with gemcitabine alone. Although limited activity of docetaxel in patients with pancreatic adenocarcinoma has been reported in single-agent studies, attractive efficacy results have been documented with docetaxel in combination with other chemotherapeutic agents for the management of advanced pancreatic cancer. Phase I and II trials of docetaxel in combination with gemcitabine, irinotecan, 5-fluorouracil, or thalidomide, as well as trials of docetaxel and radiotherapy, suggest that docetaxel combinations in pancreatic cancer should be further studied in randomized trials.

AB - The poor outcome of pancreatic cancer with conventional treatment options emphasizes the need for continued research. The benefits of gemcitabine in improving quality of life and survival have been established in patients with advanced pancreatic cancer. Randomized clinical trials studying the addition of a second drug to gemcitabine, either a classic cytotoxic (5-fluorouracil, cisplatin, irinotecan, pemetrexed, oxaliplatin, or exatecan) or targeted agents (ie, the farnesyl transferase inhibitor R115777 or the metalloproteinase inhibitor marimastat) have not resulted in improvement in survival compared with gemcitabine alone. Although limited activity of docetaxel in patients with pancreatic adenocarcinoma has been reported in single-agent studies, attractive efficacy results have been documented with docetaxel in combination with other chemotherapeutic agents for the management of advanced pancreatic cancer. Phase I and II trials of docetaxel in combination with gemcitabine, irinotecan, 5-fluorouracil, or thalidomide, as well as trials of docetaxel and radiotherapy, suggest that docetaxel combinations in pancreatic cancer should be further studied in randomized trials.

UR - http://www.scopus.com/inward/record.url?scp=19444387950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19444387950&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2005.04.003

DO - 10.1053/j.seminoncol.2005.04.003

M3 - Article

C2 - 16015551

AN - SCOPUS:19444387950

VL - 32

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 4

ER -